The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base

BACKGROUND: Tumor mutation burden (TMB) is novel biomarker of promising predict value in prediction of immune checkpoint inhibitors (ICPis) in non-small cell lung cancer (NSCLC). However, the distribution of TMB in epidermal growth factor receptor (EGFR)-mutant advanced lung adenocarcinoma (LUAD) pa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Dis
Main Authors: Jiao, Xiao-Dong, He, Xi, Qin, Bao-Dong, Liu, Ke, Wu, Ying, Liu, Jun, Hou, Ting, Zang, Yuan-Sheng
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6940222/
https://ncbi.nlm.nih.gov/pubmed/31903239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2019.11.04
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados